Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · Real-Time Price · USD

7.60

+0.48 (6.74%)

At close: Dec 10, 2025, 4:00 PM EST

7.57

-0.03 (-0.39%)

After-hours: Dec 10, 2025, 4:00 PM EST

Kalaris Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	15.04	6.69	1.76	2.24
Research & Development	27.45	45.04	11.71	11.76
Operating Expenses	42.48	51.73	13.46	14.01
Operating Income	-42.48	-51.73	-13.46	-14.01
Interest Expense	-38.82	-40.72	-1.58	-1.03
Other Non Operating Income (Expenses)	25.84	23.28	0.34	0.75
EBT Excluding Unusual Items	-55.47	-69.17	-14.7	-14.29
Other Unusual Items	-	-	-	-1.2
Pretax Income	-55.47	-69.17	-14.7	-15.49
Net Income	-55.47	-69.17	-14.7	-15.49
Net Income to Common	-55.47	-69.17	-14.7	-15.49
Shares Outstanding (Basic)	16	7	6	4
Shares Outstanding (Diluted)	16	7	6	4
Shares Change (YoY)	514.28%	9.18%	36.56%	-
EPS (Basic)	-3.46	-10.44	-2.42	-3.48
EPS (Diluted)	-3.46	-10.44	-2.42	-3.48
EBIT	-42.48	-51.73	-13.46	-14.01

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q